Dihydropyrimidine dehydrogenase

Definition

Dihydropyrimidine dehydrogenase (DPD) is an enzyme that plays a crucial role in the catabolism of pyrimidines, specifically by catalyzing the reduction of dihydropyrimidines to their corresponding pyrimidine derivatives. This enzyme is essential for the metabolism of uracil and thymine, which are key components of nucleic acids. The proper functioning of DPD is vital for maintaining the balance of pyrimidine levels in the body, influencing both pyrimidine biosynthesis and degradation processes.

5 Must Know Facts For Your Next Test

1. Dihydropyrimidine dehydrogenase is primarily located in the liver and plays a key role in the breakdown of pyrimidines.
2. A deficiency in DPD can lead to toxicity when using certain chemotherapeutic agents like 5-fluorouracil, as it inhibits the enzyme's activity.
3. DPD catalyzes the first step in the catabolism of uracil and thymine, converting them into dihydropyrimidines.
4. The activity of DPD is regulated by various factors, including substrates and metabolic needs, ensuring proper pyrimidine balance.
5. Genetic variations in the DPD gene can affect an individual's response to certain medications, making pharmacogenomic testing relevant in personalized medicine.

Review Questions

• What role does dihydropyrimidine dehydrogenase play in the metabolism of pyrimidines?
  • Dihydropyrimidine dehydrogenase (DPD) is crucial for the metabolism of pyrimidines as it catalyzes the reduction of dihydropyrimidines into their respective pyrimidine derivatives. This reaction is essential for breaking down uracil and thymine, thus allowing for their eventual excretion or recycling within cellular processes. The enzyme ensures that pyrimidine levels remain balanced, supporting various biological functions.
• Discuss the implications of dihydropyrimidine dehydrogenase deficiency on drug metabolism.
  • A deficiency in dihydropyrimidine dehydrogenase can significantly affect drug metabolism, especially for chemotherapeutic agents like 5-fluorouracil. Since DPD is responsible for degrading this drug, a deficiency leads to increased drug levels in the body, resulting in severe toxicity and adverse effects. Understanding DPD activity is therefore critical for optimizing treatment regimens and minimizing potential harm from medications.
• Evaluate how genetic variations in the dihydropyrimidine dehydrogenase gene can influence personalized medicine approaches.
  • Genetic variations in the dihydropyrimidine dehydrogenase gene can lead to differences in enzyme activity among individuals, significantly impacting how patients respond to certain medications. For instance, those with reduced DPD activity may experience heightened sensitivity to drugs like 5-fluorouracil, necessitating dose adjustments or alternative therapies. This variability underscores the importance of pharmacogenomic testing as a personalized medicine approach to tailor treatments based on an individual's genetic profile and minimize adverse drug reactions.

Related terms

Pyrimidine: A nitrogenous base that is one of the two categories of bases found in nucleic acids, including uracil, cytosine, and thymine.

Thymidine: A nucleoside that consists of thymine attached to a deoxyribose sugar, which is a building block for DNA.

Ureidopropionic acid: An intermediate in the catabolic pathway of pyrimidines that is formed through the action of several enzymes including DPD.